Appellate Board upholds compulsory licence of cancer drug
The Hindu reports that India’s Intellectual Property Appellate Board has upheld the decision of the Controller of Patents to issue a compulsory licence for Bayer’s Nexavar. The most interesting part of the proceeding might be Bayer’s contention that Natco (the generic producer) is selling its version in China and Pakistan (the Appellate Board refused to consider …
Appellate Board upholds compulsory licence of cancer drug Read More »